
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD is a direct-to-patient healthcare company that provides convenient and cost-effective virtual medical care and pharmacy services. Despite reporting lower than expected revenue and adjusted EBITDA in 2Q26, the company made significant investments in new initiatives such as transitioning to branded GLP-1s and expanding into women's health, highlighting its commitment to sustainable long-term growth. With a strong cash position and a growing telehealth platform, LifeMD seems well-positioned to capitalize on the demand for direct-to-consumer healthcare services.
Bears say
LifeMD is facing challenges with obtaining a positive ROI from its investments, impacting profitability and leading to a miss in topline for Q2 2026 and a lowering of FY2026 revenue guidance. While the recent FDA committee decisions are expected to provide a boost, they will not significantly contribute until 2027. The company also faced pressures in Q2, with high CACs and competition in the weight loss market, but potential growth in other product categories.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares